Over 50% of cutaneous melanomas harbor BRAF mutations, which can induce an enhancement of the kinase action that, consequently, leads to activation and augmentation of the downstream MAPK signaling pathway [7,12]. The gene discussed is BRAF; the disease is cutaneous melanoma.